Glossary
68 key terms · definitions · clinical pearls
Filter by category
68 terms found
A
Acute Inflammation
Inflammation
Rapid, short-lived response to injury with vascular changes, edema, and neutrophil infiltration. Cardinal signs: rubor, calor, tumor, dolor, functio laesa.
Pearl
Neutrophils dominate at 6–24 hours via chemotaxis (C5a, LTB4, IL-8).
NEW3-Step Formula
§1 Define · Acute inflammation is a rapid, short-lived immune response characterized by the exudation of fluid and plasma proteins and the emigration of leukocytes, primarily neutrophils.
§2 Mechanism · The process begins with the vascular phase where histamine and bradykinin induce vasodilation and increased vascular permeability, forming a protein-rich exudate. This is followed by the cellular phase, where neutrophils undergo margination, rolling via selectins, and firm adhesion via integrins (ICAM-1/VCAM-1) before transmigrating. Chemotactic factors like IL-8, C5a, and LTB4 guide neutrophils to the site of injury to eliminate pathogens via phagocytosis and ROS production.
§3 Clinical + Test · A clinical example is bacterial pneumonia, resulting in pleural empyema; diagnosis is confirmed by pleural fluid analysis showing an exudate (Light's criteria) and elevated neutrophils.
Anaplasia
Neoplasia
Loss of structural and functional differentiation. Hallmark of malignancy.
Pearl
Includes pleomorphism, hyperchromasia, abnormal mitoses, ↑N:C ratio.
NEW3-Step Formula
§1 Define · Anaplasia is a hallmark of malignancy defined by a lack of differentiation, where cells lose the specialized structural and functional characteristics of their tissue of origin. It is considered the most extreme form of cellular atypia and is a reliable indicator of aggressive behavior.
§2 Mechanism · The mechanism involves profound alterations in cell morphology and polarity, characterized by pleomorphism (variation in size and shape) and an increased nuclear-to-cytoplasmic (N/C) ratio. Chromatin becomes coarse and hyperchromatic, nucleoli become prominent, and mitoses are frequent and often atypical or tripolar. These changes reflect a massive destabilization of the cytoskeleton and gene expression programs that normally maintain cell identity.
§3 Clinical + Test · A clinical example is anaplastic thyroid carcinoma, which is highly aggressive and carries a poor prognosis. Diagnosis is confirmed via biopsy and histopathological examination; immunohistochemistry may be used to identify the origin if the tumor is highly undifferentiated.
Anemia Classification
Anemia
NEW · Classified by MCV: MICROCYTIC (<80 fL — iron deficiency, thalassemia, ACD, sideroblastic, lead); NORMOCYTIC (80–100 — acute blood loss, hemolysis, marrow failure, CKD); MACROCYTIC (>100 — B12/folate, alcohol, hypothyroid, MDS).
Pearl
Normal Hb: M 13.5–17.5 g/dL · F 12.0–15.5 g/dL. Reticulocyte index distinguishes hypoproliferative (<2) from hyperproliferative (>2) anemias.
NEW3-Step Formula
§1 Define · Anemia is a reduction in red blood cell mass or hemoglobin concentration below age- and sex-specific reference ranges, defined by WHO as Hb < 13 g/dL in men and < 12 g/dL in non-pregnant women.
§2 Mechanism · Classification follows a morphologic (MCV-based) AND kinetic (reticulocyte response) approach. MICROCYTIC HYPOCHROMIC (MCV < 80, MCH < 27): iron-deficiency anemia is most common — ↓ ferritin, ↓ serum Fe, ↑ TIBC, ↓ transferrin saturation, ↑ RDW. Thalassemia shows normal ferritin and abnormal Hb electrophoresis. NORMOCYTIC: subdivide by retic count — high retic = hemolysis (↑ LDH, ↑ indirect bilirubin, ↓ haptoglobin) or acute blood loss; low retic = marrow failure or CKD (↓ EPO). MACROCYTIC: megaloblastic from B12/folate deficiency shows hypersegmented neutrophils and ovalocytes; non-megaloblastic from alcohol, hypothyroidism, MDS, reticulocytosis. Symptoms reflect tissue hypoxia: pallor, fatigue, dyspnea, tachycardia, pica, glossitis, koilonychia, neurologic signs in B12 deficiency.
§3 Clinical + Test · Workup: CBC + peripheral smear, retic count, iron panel + ferritin, B12/folate, LDH, haptoglobin, Coombs if hemolysis, Hb electrophoresis, marrow biopsy if unexplained. Treat the cause: oral/IV iron, B12 IM injections, EPO in CKD, transfusion if symptomatic.
Angiogenesis
Neoplasia
Formation of new vessels. Essential for tumors >1–2 mm.
Pearl
VEGF is master switch. Bevacizumab is anti-VEGF antibody.
NEW3-Step Formula
§1 Define · Angiogenesis is the physiological or pathological process of forming new blood vessels from pre-existing ones, essential for wound healing and tumor growth beyond 1-2 mm. In neoplasia, it is driven by an 'angiogenic switch' where pro-angiogenic factors outweigh inhibitors.
§2 Mechanism · Tumor hypoxia stabilizes HIF-1α, which translocates to the nucleus to induce the transcription of VEGF. VEGF binds to Receptor Tyrosine Kinases (VEGFR) on nearby endothelial cells, stimulating their proliferation, migration, and secretion of Matrix Metalloproteinases (MMPs) to degrade the basement membrane. This results in the formation of leaky, disorganized capillary sprouts that provide oxygen and nutrients to the expanding tumor mass.
§3 Clinical + Test · Abundant angiogenesis is seen in Wet Age-Related Macular Degeneration and various solid tumors. Diagnosis is often through imaging or CD31/CD34 immunohistochemical staining of tissue; Bevacizumab (Avastin) is a monoclonal antibody used to neutralize VEGF and inhibit this process.
Apoptosis
Cell Death
Programmed, ATP-dependent cell death with intact membrane, cell shrinkage, chromatin condensation, apoptotic body formation. Does NOT trigger inflammation.
Pearl
Intrinsic: DNA damage → BAX/BAK → cyto-c → apoptosome → caspase-9 → caspase-3. Extrinsic: Fas/FasL → caspase-8.
NEW3-Step Formula
§1 Define · Apoptosis is a pathway of programmed cell death characterized by nuclear dissolution and fragmentation of the cell without loss of membrane integrity or eliciting an inflammatory response.
§2 Mechanism · The intrinsic (mitochondrial) pathway is triggered by DNA damage or growth factor withdrawal, leading to p53 activation and a pro-apoptotic shift in BCL-2 family proteins (BAX/BAK). These proteins permeabilize the mitochondrial membrane, releasing Cytochrome c, which activates the apoptosome and caspase-9. caspases act as executioner enzymes (caspase-3, 6, 7) that cleave cellular proteins and activate endonucleases, leading to DNA laddering and apoptotic body formation for macrophage clearance.
§3 Clinical + Test · Follicular lymphoma is a clinical example where a t(14;18) translocation overexpresses BCL-2, inhibiting apoptosis; diagnosis involves FISH for the translocation, and treatment may include venetoclax to inhibit BCL-2.
Atheroma
Cardiovascular
NEW · Mature atherosclerotic plaque — raised intimal lesion with a soft lipid/necrotic core covered by a fibrous cap of SMCs, collagen, and macrophages.
Pearl
Vulnerable plaque = thin cap, large lipid core, many macrophages → ruptures → acute coronary syndrome.
NEW3-Step Formula
§1 Define · An atheroma is the characteristic lesion of atherosclerosis: a focal, raised plaque within the intima of an artery, composed of a central soft yellow lipid core and an overlying firm fibrous cap.
§2 Mechanism · Components: (i) fibrous cap of smooth muscle cells, dense collagen, elastin and proteoglycans; (ii) cellular zone of macrophages, foam cells, T cells, and SMCs at the shoulder; (iii) necrotic core of cellular debris, cholesterol crystals (clefts on histology), calcium, and ox-LDL. Plaque grows by lipid accumulation, SMC proliferation, and neovascularization. Stable plaques have thick caps; vulnerable plaques have thin caps and large cores — MMP-9 from macrophages digests the cap, exposing tissue factor and triggering platelet-rich thrombosis. Outcomes: stenosis → angina/claudication, rupture → MI/stroke, weakening → aneurysm.
§3 Clinical + Test · Detect with IVUS, OCT, coronary CTA. Manage with statins (regress lipid core, thicken cap), aspirin, ACEi, smoking cessation; revascularize with PCI or CABG when symptomatic.
Atherosclerosis
Cardiovascular
NEW · Chronic inflammatory disease of large/medium elastic and muscular arteries characterized by intimal lipid plaques (atheromas) causing stenosis, thrombosis, and aneurysm.
Pearl
Driven by LDL cholesterol + endothelial injury. Major risks: smoking, HTN, diabetes, hyperlipidemia, age, male sex, family history.
NEW3-Step Formula
§1 Define · Atherosclerosis is a chronic, progressive inflammatory disease of the arterial intima in which lipid, smooth muscle cells, macrophages, and ECM accumulate to form atheromatous plaques, the leading cause of myocardial infarction, stroke, and peripheral vascular disease.
§2 Mechanism · Endothelial injury (shear stress at bifurcations, smoking, hyperglycemia, HTN, ox-LDL) → ↑ permeability and adhesion molecule expression (VCAM-1) → LDL infiltrates intima and is oxidized → monocytes adhere, transmigrate, and engulf ox-LDL via scavenger receptors (CD36, SR-A) becoming FOAM CELLS → fatty streak. Foam cells release IL-1, TNF, PDGF, FGF → smooth muscle cells migrate from media to intima and synthesize collagen → fibrous cap forms over a necrotic lipid core. Plaque rupture exposes thrombogenic core → acute thrombosis → MI or stroke.
§3 Clinical + Test · Diagnose with lipid panel (LDL, HDL, ApoB), coronary calcium score, CT/cath angiography. Treat with high-intensity statin (atorvastatin/rosuvastatin), PCSK9 inhibitors, antiplatelets, BP/glucose control, lifestyle.
ATM
Tumor Suppressors
NEW · Ataxia-Telangiectasia Mutated — serine/threonine kinase that senses double-strand DNA breaks and activates p53, CHK2, BRCA1, H2AX.
Pearl
Germline biallelic ATM loss = Ataxia-Telangiectasia (cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, lymphoma risk). Heterozygotes have ↑ breast cancer risk.
NEW3-Step Formula
§1 Define · ATM (Ataxia-Telangiectasia Mutated) is a PI3K-like serine/threonine kinase encoded on 11q22-23 that functions as the master sensor of DNA double-strand breaks.
§2 Mechanism · Upon DSB detection by the MRN complex (MRE11–RAD50–NBS1), ATM autophosphorylates and activates a damage-response cascade: it phosphorylates p53 (Ser15) — freeing it from MDM2 — and CHK2, BRCA1, and histone H2AX (γH2AX foci). This halts the cell cycle at G1/S and G2/M, recruits HR machinery, and either repairs the lesion or commits to apoptosis. Loss disables this checkpoint, producing genomic instability and immunodeficiency from defective V(D)J recombination.
§3 Clinical + Test · A-T patients show ↑ AFP, cerebellar atrophy on MRI, ↓ IgA, lymphoid malignancy. Diagnosis: NGS for ATM, colony-survival assay; avoid ionizing radiation. Carriers benefit from MRI breast screening.
Autophagy
Cell Death
Cellular self-digestion: autophagosome → fuses with lysosome → degrades damaged organelles. Activated by starvation (AMPK↑, mTOR↓).
Pearl
Dual role in cancer — tumor-suppressive early, tumor-promoting in established disease.
NEW3-Step Formula
§1 Define · Autophagy is an evolutionarily conserved lysosomal degradation pathway where the cell recycles its own components (organelles and proteins) to maintain homeostasis during nutrient deprivation or stress.
§2 Mechanism · The process is initiated by the inhibition of mTOR or activation of AMPK, leading to the formation of a double-membrane isolation structure called a phagophore. The phagophore expands and engulfs cytoplasmic cargo to form an autophagosome, a process mediated by LC3-II and Atg proteins. The autophagosome then fuses with a lysosome to form an autolysosome, where acid hydrolases degrade the contents to provide amino acids and fatty acids for ATP production.
§3 Clinical + Test · In neurodegenerative diseases like Alzheimer's, defective autophagy leads to the accumulation of misfolded protein aggregates; research into autophagy enhancers is a potential therapeutic strategy.
Autosomal Dominant
Genetics
One mutated allele is sufficient. Affects both sexes, vertical transmission, 50% offspring risk.
Pearl
Marfan (FBN1), NF1, Huntington (CAG), BRCA1/2, Li-Fraumeni (TP53).
NEW3-Step Formula
§1 Define · Autosomal dominant (AD) inheritance occurs when a single mutant allele on a non-sex chromosome is sufficient to cause the disease phenotype, typically characterized by vertical transmission in a pedigree.
§2 Mechanism · The mechanism often involves a gain-of-function mutation (e.g., constitutive activation of a receptor) or a dominant-negative effect where the mutant protein interferes with the function of the wild-type protein. In some cases, haploinsufficiency occurs, where 50% of the normal protein product is inadequate for normal function. AD traits frequently exhibit variable expressivity or incomplete penetrance, where the gene is present but the phenotype may be subtle or absent.
§3 Clinical + Test · Achondroplasia is a classic AD condition caused by a gain-of-function G380R mutation in FGFR3; diagnosis is confirmed via Sanger sequencing of the specific hotspot.
Autosomal Recessive
Genetics
Both alleles mutated. Carrier parents asymptomatic; 25% affected offspring; horizontal pattern in siblings.
Pearl
CF (CFTR ΔF508), thalassemias, sickle cell, PKU, Tay-Sachs.
NEW3-Step Formula
§1 Define · Autosomal recessive (AR) inheritance occurs when two mutant alleles at the same locus are required to express the phenotype, typically resulting from loss-of-function mutations in both copies of a gene.
§2 Mechanism · The mechanism generally involves the complete loss or significant reduction of a functional protein, such as an enzyme or a channel, which the cell cannot compensate for with only a 50% dosage. Affected individuals are usually the offspring of two asymptomatic carrier parents (25% risk), and the pedigree typically shows horizontal transmission. Consanguinity increases the risk of AR disorders by increasing the likelihood of inheriting identical mutant alleles from a common ancestor.
§3 Clinical + Test · Cystic Fibrosis is an AR disease caused by mutations in the CFTR gene, most commonly the ΔF508 deletion; diagnosis is made via sweat chloride testing and NGS panels, with Trikafta used to improve protein folding.
B
BCL-2 Family
Cell Death
Regulators of mitochondrial apoptosis. Pro-apoptotic: BAX, BAK, BID, BIM. Anti-apoptotic: BCL-2, BCL-XL, MCL-1.
Pearl
BCL-2 translocation t(14;18) defines follicular lymphoma.
NEW3-Step Formula
§1 Define · The BCL-2 family consists of pro-apoptotic and anti-apoptotic proteins that serve as the 'molecular switches' governing the intrinsic (mitochondrial) pathway of apoptosis. Pathological overexpression is frequently associated with dominant gain-of-function survival in cancer.
§2 Mechanism · Bax and Bak (pro-apoptotic) form pores in the mitochondrial outer membrane to release Cytochrome c, while BCL-2 and BCL-XL (anti-apoptotic) normally sequester them to prevent pore formation. DNA damage or growth factor withdrawal activates BH3-only sensors (like BIM or PUMA) which inhibit BCL-2, allowing Bax/Bak to trigger the caspase cascade through the apoptosome. Overexpression of BCL-2 prevents this release, rendering cells resistant to death signals.
§3 Clinical + Test · A classic example is Follicular Lymphoma, caused by the t(14;18) translocation that places BCL-2 under the IgH promoter. FISH is used to detect the translocation; Venetoclax is a targeted BCL-2 inhibitor used to induce apoptosis in these cells.
Breast Cancer
Hormone Malignancies
NEW · Heterogeneous malignancy of breast ductal/lobular epithelium. Molecular subtypes: Luminal A (ER+/PR+/HER2−), Luminal B, HER2-enriched, Triple-negative/basal-like.
Pearl
BRCA1 → triple-negative basal-like; BRCA2 → ER+. Men with breast cancer → suspect BRCA2 (or BRCA1). Trastuzumab for HER2+; tamoxifen/AI for ER+; PARPi for BRCA.
NEW3-Step Formula
§1 Define · Breast cancer is the most common malignancy in women worldwide, arising from the epithelium of the terminal ductal-lobular unit; it is biologically and molecularly heterogeneous with distinct prognoses and therapies per subtype.
§2 Mechanism · Risk factors: ↑ lifetime estrogen exposure (early menarche, late menopause, nulliparity, HRT), age, family history, germline BRCA1/BRCA2, TP53 (Li-Fraumeni), PTEN (Cowden), CHEK2, PALB2, and prior chest radiation. Histology: ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC, ~75%); lobular carcinoma in situ (LCIS) and invasive lobular carcinoma (ILC, E-cadherin LOSS, single-file pattern). MOLECULAR/IHC subtypes: LUMINAL A (ER+/PR+/HER2−/low Ki-67 — best prognosis, endocrine therapy responsive); LUMINAL B (ER+/HER2± /high Ki-67); HER2-ENRICHED (ERBB2 amplification 17q12 — aggressive, trastuzumab-responsive); TRIPLE-NEGATIVE/BASAL-LIKE (ER−/PR−/HER2− — chemo-sensitive, BRCA1-associated, poor prognosis, PARPi/pembrolizumab option). Driver pathways: ER/PR signaling, HER2 → MAPK/PI3K, BRCA1/2 → HR-repair loss. Metastasis: bone (osteolytic/blastic), liver, lung, brain (HER2+/TNBC).
§3 Clinical + Test · Screening: mammography q2 yr 50–74 (earlier with BRCA + MRI). Diagnosis: triple assessment (clinical exam + imaging + core biopsy with ER/PR/HER2/Ki-67). Treatment matched to subtype: surgery + RT + endocrine (tamoxifen, AI), trastuzumab + pertuzumab (HER2+), chemotherapy, PARP inhibitors (olaparib for BRCA+), pembrolizumab (PD-L1+ TNBC).
C
Caseous Necrosis
Cell Death
Cheese-like, friable necrotic tissue with granulomatous inflammation.
Pearl
Classic for TB. Also fungal infections (histoplasmosis).
NEW3-Step Formula
§1 Define · Caseous necrosis is a distinctive form of cell death characterized by a 'cheese-like,' friable white appearance, typically associated with granulomatous inflammation. It represents a subacute or chronic response to specific pathogens that the body cannot easily eliminate.
§2 Mechanism · The mechanism involves a persistent immune response where macrophages encounter lipid-rich mycobacterial cell walls, which are resistant to digestion. CD4+ Th1 cells release IFN-γ to activate these macrophages into epithelioid cells and Langhans giant cells, which sequester the pathogen. The combination of chronic inflammation and delayed-type hypersensitivity leads to a central zone of acellular, eosinophilic debris where the tissue architecture is completely obliterated.
§3 Clinical + Test · The quintessential example is Mycobacterium tuberculosis infection. Diagnosis is made via a sputum culture, Chest X-ray, or Ziehl-Neelsen stain (Acid-Fast Bacilli); treatment involves a multi-drug regimen including Isoniazid and Rifampin.
Chemotaxis
Inflammation
NEW · Directional migration of leukocytes along a chemical gradient toward the site of injury or infection.
Pearl
Key chemoattractants: C5a, LTB4, IL-8 (CXCL8), bacterial fMLP, chemokines (CXCL/CCL families).
NEW3-Step Formula
§1 Define · Chemotaxis is the directed locomotion of cells, particularly leukocytes, along an increasing gradient of soluble chemoattractants — a defining step of the cellular phase of acute inflammation.
§2 Mechanism · Chemoattractants bind G-protein-coupled receptors on leukocytes → activation of PI3K, Rac/Rho/Cdc42, and PLCγ → assembly of actin filaments at the leading edge (lamellipodia) and contraction at the trailing uropod via myosin. Calcium flux mobilizes integrins (LFA-1, Mac-1) to high-affinity states for firm adhesion. Major chemoattractants: exogenous = bacterial N-formyl-methionyl peptides (fMLP); endogenous = complement C5a, leukotriene B4 (LTB4), interleukin-8 (CXCL8) for neutrophils, eotaxin (CCL11) for eosinophils, MCP-1 (CCL2) for monocytes.
§3 Clinical + Test · Defective chemotaxis = recurrent bacterial infections: leukocyte adhesion deficiency (LAD-1, β2-integrin defect), Chédiak-Higashi (LYST). Diagnose with flow cytometry for CD18; clinically test with Boyden chamber assay.
Chronic Inflammation
Inflammation
Prolonged response with macrophages, lymphocytes, plasma cells, tissue destruction, repair, fibrosis.
Pearl
M1 macrophages: pro-inflammatory (IFN-γ). M2: tissue repair (IL-4, IL-13).
NEW3-Step Formula
§1 Define · Chronic inflammation is a prolonged inflammatory response (weeks to months) characterized by simultaneous tissue injury, repair, and immune infiltration. It is dominated by macrophages, lymphocytes, and plasma cells rather than neutrophils.
§2 Mechanism · Persistent stimuli drive CD4+ Th1 cells to release IFN-γ, which activates M1 macrophages to produce ROS, TNF, and IL-1. Simultaneously, M2 macrophages release TGF-β and PDGF to stimulate myofibroblast activation and collagen deposition. This imbalance between chronic destruction and defective healing leads to tissue replacement by fibrous connective tissue.
§3 Clinical + Test · A classic example is Liver Cirrhosis resulting from chronic HCV infection. Diagnosis is supported by biopsy showing bridging fibrosis or elastography, and management focuses on removing the irritant or using anti-fibrotic agents.
Coagulative Necrosis
Cell Death
Tissue architecture preserved as 'tombstones' due to protein denaturation. Most ischemic infarcts.
Pearl
Exception: brain (liquefactive). Heart, kidney, spleen → coagulative.
NEW3-Step Formula
§1 Define · Coagulative necrosis is the most common form of necrosis, typically resulting from sudden ischemia or infarction in all solid organs except the brain. It is characterized by the preservation of basic tissue architecture for several days despite cell death.
§2 Mechanism · Ischemia leads to a rapid drop in intracellular pH, which denatures both structural proteins and enzymatic (lysosomal) proteins. Because the digestive enzymes are themselves inactivated, the 'ghost-like' outlines of the dead cells persist until inflammatory leucocytes eventually arrive to phagocytose the debris. This process converts the affected tissue into a firm, pale mass.
§3 Clinical + Test · A Myocardial Infarction (MI) is the classic clinical example. Diagnosis is achieved through ECG changes and elevated serum Troponin levels; urgent reperfusion therapy (e.g., PCI or fibrinolytics) is the primary therapeutic intervention.
D
Diabetes Mellitus
Diabetes
Group of metabolic disorders with chronic hyperglycemia from defects in insulin secretion, action, or both.
Pearl
Diagnostic: FPG ≥126, OGTT ≥200, HbA1c ≥6.5, random ≥200 + symptoms.
NEW3-Step Formula
§1 Define · Diabetes Mellitus is a group of metabolic disorders characterized by chronic hyperglycemia resulting from absolute insulin deficiency (Type 1) or relative deficiency and insulin resistance (Type 2). It is a chronic systemic disease with profound microvascular and macrovascular consequences.
§2 Mechanism · In T1DM, autoimmune destruction of beta-cells by CD8+ T cells eliminates insulin production. In T2DM, obesity-induced inflammation and lipotoxicity impair GLUT4 translocation and promote hepatic gluconeogenesis. Chronic hyperglycemia leads to the formation of Advanced Glycation End-products (AGEs) that bind RAGE, inducing oxidative stress and endothelial dysfunction.
§3 Clinical + Test · A clinical outcome is Diabetic Foot Gangrene caused by peripheral arterial disease. Diagnosis is confirmed via Glycated Hemoglobin (HbA1c ≥ 6.5%) or a fasting plasma glucose test.
DiGeorge Syndrome
Genetics
22q11.2 deletion. CATCH-22: Cardiac, Abnormal facies, Thymic aplasia, Cleft palate, Hypocalcemia.
Pearl
Failure of 3rd/4th pharyngeal pouches. T-cell deficiency.
NEW3-Step Formula
§1 Define · DiGeorge Syndrome (22q11.2 Deletion Syndrome) is a microdeletion syndrome caused by the loss of approximately 30-50 genes on chromosome 22. It is typically a sporadic, autosomal dominant structural abnormality affecting the development of the third and fourth pharyngeal pouches.
§2 Mechanism · The deletion of the TBX1 transcription factor disrupts multisystem development, specifically affecting the thymus, parathyroid glands, and heart. This results in T-cell deficiency (thymic hypoplasia), hypocalcemia (parathyroid hypoplasia), and conotruncal cardiac defects. The loss of genetic material leads to haploinsufficiency of critical developmental regulators.
§3 Clinical + Test · A clinical example is a neonate presenting with tetralogy of Fallot and hypocalcemic seizures. The gold standard diagnostic test is FISH (Fluorescent In Situ Hybridization) or CGH-array to detect the sub-microscopic 22q11.2 deletion.
E
Edema
Hemodynamics
NEW · Abnormal accumulation of interstitial fluid due to imbalance of Starling forces, lymphatic obstruction, sodium retention, or inflammation.
Pearl
Transudate (protein < 3 g/dL, SG < 1.012) = hemodynamic; Exudate (protein > 3 g/dL, SG > 1.020) = inflammatory.
NEW3-Step Formula
§1 Define · Edema is the accumulation of excess fluid in the interstitial compartment or body cavities, resulting from disruption of the Starling equilibrium between hydrostatic and oncotic pressures.
§2 Mechanism · Mechanisms: (1) ↑ hydrostatic pressure (CHF, portal hypertension, DVT); (2) ↓ plasma oncotic pressure (cirrhosis, nephrotic syndrome, malnutrition → hypoalbuminemia); (3) lymphatic obstruction (filariasis, post-mastectomy); (4) Na⁺/H₂O retention (renal failure, RAAS activation); (5) ↑ vascular permeability (inflammation — histamine, bradykinin). Pulmonary edema impairs gas exchange; cerebral edema raises ICP.
§3 Clinical + Test · Pitting peripheral edema in CHF; ascites in cirrhosis; periorbital edema in nephrotic syndrome. Diagnosis: Light's criteria on pleural tap (protein/LDH ratios); treatment targets the cause (diuretics, albumin, lymphatic drainage).
EMT
Metastasis
Epithelial-Mesenchymal Transition: loss of E-cadherin, gain of N-cadherin/vimentin, gain of motility.
Pearl
Driven by Snail, Slug, Twist, ZEB1/2. Critical step in invasion.
NEW3-Step Formula
§1 Define · Epithelial-Mesenchymal Transition (EMT) is a biological process where polarized epithelial cells lose their adhesion and gain a migratory, mesenchymal phenotype. In oncology, it is a critical driver of the metastatic cascade.
§2 Mechanism · TGF-β or hypoxia induces transcription factors like SNAIL, SLUG, and TWIST. These factors repress E-cadherin (loss of cell-cell junctions) and upregulate N-cadherin and vimentin (gain of motility). The cell degrades the basement membrane via MMPs to move into the stroma and eventually intravasate into circulation.
§3 Clinical + Test · This process is essential for the colonization of distant organs in carcinomas, such as breast cancer. Diagnostic markers for EMT in tissue include a loss of E-cadherin and gain of α-SMA or N-cadherin via immunohistochemistry.
Exosome
Exosomes
30–150 nm extracellular vesicle derived from MVB. Carries proteins, mRNA, miRNA.
Pearl
Tumor exosomes prepare the pre-metastatic niche.
NEW3-Step Formula
§1 Define · Exosomes are small (30–150 nm) extracellular vesicles of endocytic origin that facilitate intercellular communication by transporting proteins, lipids, and nucleic acids. In the tumor microenvironment (TME), they serve as mediators of horizontal gene transfer and systemic signaling.
§2 Mechanism · They form via the inward budding of multivesicular bodies (MVBs) and are released into the extracellular space upon fusion with the plasma membrane. Once released, they protect their cargo (e.g., microRNAs, oncogenic proteins) from degradation. Recipient cells take them up via endocytosis or membrane fusion, altering their gene expression and promoting phenomena like the pre-metastatic niche.
§3 Clinical + Test · Tumor-derived exosomes can carry EGFRvIII or PD-L1 to suppress local immune responses. They are currently being investigated as 'liquid biopsies' where circulating exosomes are isolated from blood to detect cancer-specific mutations via NGS.
Exudate
Inflammation
NEW · High-protein (>3 g/dL), cell-rich inflammatory fluid from ↑ vascular permeability. Subtypes: serous, fibrinous, purulent (pus), hemorrhagic, fibrinoid.
Pearl
Light's criteria POSITIVE — protein ratio >0.5, LDH ratio >0.6. Driven by histamine, bradykinin, leukotrienes, complement.
NEW3-Step Formula
§1 Define · An exudate is an inflammatory extravascular fluid rich in protein (> 3 g/dL) and cellular debris, with a specific gravity > 1.020, produced when increased vascular permeability allows plasma proteins and leukocytes to escape into tissues.
§2 Mechanism · Histamine, bradykinin, C3a/C5a, and leukotrienes induce endothelial cell contraction → widening of post-capillary venule junctions. Five morphologic subtypes: SEROUS (thin, protein-poor — early burn blisters, viral pleurisy); FIBRINOUS (fibrin-rich — uremic/post-MI pericarditis, 'bread-and-butter'); PURULENT/SUPPURATIVE (neutrophil-rich PUS — pyogenic abscess, empyema); HEMORRHAGIC (RBC-rich — tuberculous pleuritis, malignancy, severe pancreatitis); FIBRINOID (fibrin + necrosis in vessel walls — vasculitis, malignant HTN, hyperacute rejection).
§3 Clinical + Test · Diagnose with thoracentesis + Light's criteria + cytology/culture. Empyema → chest-tube drainage + antibiotics; hemorrhagic pleural effusion mandates cytology to rule out malignancy.
F
Fibrinoid Exudate
Inflammation
NEW · Bright eosinophilic deposit of fibrin + immune complexes within vessel walls — hallmark of vasculitis and malignant hypertension.
Pearl
Seen in PAN, hyperacute graft rejection, malignant HTN, scleroderma renal crisis, preeclampsia.
NEW3-Step Formula
§1 Define · Fibrinoid exudate (fibrinoid necrosis) is a histologic pattern showing smudgy, bright pink (eosinophilic) deposits of fibrin admixed with necrotic vessel wall, characteristic of immune-complex-mediated vascular injury.
§2 Mechanism · Circulating antigen-antibody complexes deposit in arteriolar walls, activate complement (C3a/C5a), recruit neutrophils, and trigger type III hypersensitivity. Released ROS and proteases destroy the media, allowing fibrin to permeate; smooth muscle is replaced by amorphous eosinophilic material. In malignant HTN, extreme pressure mechanically damages endothelium, plasma proteins insudate, and fibrinoid necrosis of afferent arterioles produces 'onion-skin' hyperplasia and AKI.
§3 Clinical + Test · Diagnose by biopsy (kidney, skin, temporal artery) — fibrinoid necrosis + leukocytoclastic vasculitis. Treat the underlying immunologic process: corticosteroids, cyclophosphamide, rituximab; aggressive BP control in malignant HTN.
Fibrosis
Cellular Adaptations
NEW · Pathologic excess deposition of extracellular matrix (collagen I/III) by activated myofibroblasts in response to chronic injury — replaces functional parenchyma with scar.
Pearl
Master cytokine = TGF-β. Antifibrotics: pirfenidone, nintedanib (IPF); ARBs ↓ TGF-β in Marfan/cardiac fibrosis.
NEW3-Step Formula
§1 Define · Fibrosis is the irreversible replacement of damaged tissue by collagen-rich extracellular matrix, the maladaptive end-result of chronic inflammation, persistent injury, or impaired regeneration.
§2 Mechanism · Chronic injury → macrophages polarize to M2 phenotype → release TGF-β, PDGF, FGF, and IL-13. TGF-β activates resident fibroblasts and tissue-specific cells (hepatic stellate cells in liver, pericytes in kidney) into α-SMA-positive MYOFIBROBLASTS that synthesize type I and III collagen and TIMPs (which inhibit MMPs). Imbalance favoring matrix deposition over degradation produces scar; concurrent vascular distortion (regenerative nodules in cirrhosis) impairs organ function. EMT also contributes (kidney/lung).
§3 Clinical + Test · Examples: hepatic cirrhosis (HCV/EtOH), idiopathic pulmonary fibrosis (UIP pattern on HRCT), keloid scars, scleroderma, chronic graft rejection. Diagnose by biopsy/imaging/elastography; treat with anti-fibrotics (pirfenidone, nintedanib), ACEi/ARB, removal of injurious stimulus.
Fragile X
Genetics
Most common inherited intellectual disability. CGG trinucleotide expansion in FMR1 (Xq27.3).
Pearl
Long face, large ears, macroorchidism. Anticipation in maternal transmission.
NEW3-Step Formula
§1 Define · Fragile X syndrome is a dynamic mutation disorder caused by the expansion of a CGG trinucleotide repeat in the 5' untranslated region of the FMR1 gene on the X chromosome.
§2 Mechanism · When repeats exceed 200 (full mutation), the CpG island becomes hypermethylated, leading to epigenetic silencing of the FMR1 gene and loss of the FMRP protein. FMRP is an RNA-binding protein essential for regulating synaptic translation; its absence results in neurodevelopmental defects and connective tissue abnormalities. Premutations (55-200 repeats) do not cause silencing but are unstable and can expand to a full mutation during maternal meiosis.
§3 Clinical + Test · A clinical example is a male with intellectual disability, macroorchidism, and large ears. Diagnosis is confirmed by PCR and Southern Blot to determine repeat sizing and methylation status.
G
Gangrenous Necrosis
Cell Death
Ischemic necrosis of a limb. Dry: coagulative. Wet: superimposed bacterial liquefactive.
Pearl
Diabetic foot, mesenteric ischemia. Treatment: debridement, antibiotics, revascularization.
NEW3-Step Formula
§1 Define · Gangrenous necrosis is a clinical term describing tissue death, typically of a limb or organ, resulting from a loss of blood supply (ischemia) followed by varying degrees of bacterial infection.
§2 Mechanism · The process begins as coagulative necrosis due to hypoxia; if it remains uncomplicated by infection, it is termed 'dry gangrene' (mummification). If saprophytic bacteria superimpose on the necrotic tissue, the release of hydrolytic enzymes by bacteria and recruited neutrophils triggers liquefactive necrosis, termed 'wet gangrene'. In Gas Gangrene, Clostridium perfringens produces alpha-toxins that cause extensive myonecrosis and gas production.
§3 Clinical + Test · A classic example is a diabetic foot ulcer progressing to black, foul-smelling tissue. Diagnosis is clinical based on physical exam and imaging for gas, often requiring surgical debridement or amputation and broad-spectrum antibiotics.
Granuloma
Inflammation
Focal collection of epithelioid macrophages, often with multinucleated giant cells and lymphocytes.
Pearl
Caseating (TB, fungi) vs non-caseating (sarcoidosis, Crohn, foreign body).
NEW3-Step Formula
§1 Define · A granuloma is a microscopic aggregate of epithelioid macrophages surrounded by a rim of lymphocytes, representing a specialized form of chronic inflammation designed to sequester indigestible agents.
§2 Mechanism · The mechanism involves a Type IV hypersensitivity reaction where APCs present persistent antigens to CD4+ Th1 cells. These lymphocytes release IFN-gamma to activate macrophages into specialized 'epithelioid' cells, which may fuse to form multinucleated Langhans giant cells. The core may undergo caseous (lipid-rich) necrosis if mycobacteria are present, or remain non-caseating in other conditions.
§3 Clinical + Test · A clinical example is Mycobacterium tuberculosis infection. Diagnosis is made via tissue biopsy (showing caseating granulomas) and Acid-Fast Bacilli (AFB) staining or quantiferon gold tests.
H
Hemoglobin (Normal Levels)
Anemia
NEW · Adult reference: Men 13.5–17.5 g/dL · Women 12.0–15.5 g/dL · Pregnancy ≥ 11 · Children ~11–14. Hct ≈ 3 × Hb.
Pearl
WHO anemia cutoff: < 13 (M), < 12 (F), < 11 (pregnant/children 6 mo–5 yr).
NEW3-Step Formula
§1 Define · Hemoglobin is the iron-containing tetrameric oxygen-transport protein in erythrocytes; its plasma concentration is the principal screening parameter for anemia and polycythemia.
§2 Mechanism · Normal adult Hb = 2 α-globin + 2 β-globin chains (HbA, 96%); minor adult forms = HbA2 (α₂δ₂, ~2.5%) and HbF (α₂γ₂, < 1%). Reference ranges: adult MEN 13.5–17.5 g/dL (Hct 41–53%), adult WOMEN 12.0–15.5 g/dL (Hct 36–46%), PREGNANT women ≥ 11 g/dL (physiologic hemodilution lowers values), NEONATES 14–24, INFANTS 9.5–13, CHILDREN 11.5–15.5. MCV 80–100 fL, MCH 27–33 pg, MCHC 32–36 g/dL, RDW 11.5–14.5%.
§3 Clinical + Test · Order CBC for routine screening. Hb < 7 g/dL = transfusion threshold in stable patients; < 8 in cardiac disease. Hb > 16.5 (F) or > 18.5 (M) warrants polycythemia workup (EPO, JAK2 V617F).
Hemorrhagic Exudate
Inflammation
NEW · Exudate with abundant RBCs — suggests vascular injury, severe inflammation, or malignancy.
Pearl
Differential: tuberculous pleuritis, pulmonary embolism with infarct, malignant effusion, severe acute pancreatitis, trauma.
NEW3-Step Formula
§1 Define · A hemorrhagic exudate is an inflammatory fluid in which red blood cells are a prominent constituent, indicating disruption of vascular integrity in addition to increased permeability.
§2 Mechanism · Mechanisms include direct vessel wall invasion (malignant cells, M. tuberculosis), enzymatic digestion of vessels (trypsin in acute hemorrhagic pancreatitis → retroperitoneal Grey-Turner/Cullen signs), infarction with capillary leak (PE with pulmonary infarct), and DIC-related microvascular bleeding. Cytology often reveals atypical cells in malignancy or acid-fast bacilli in TB.
§3 Clinical + Test · Workup: pleural/peritoneal fluid analysis (hematocrit > 50% of blood = hemothorax requiring chest tube), cytology, ADA for TB, CT angiography for PE. Treatment is cause-directed: anticoagulation for PE, anti-TB therapy, oncologic management for malignant effusions.
Histogenetic Classification
Neoplasia
NEW · (Altucci) Tumors classified by tissue of origin + behavior. Epithelial benign = adenoma/papilloma, malignant = carcinoma/adenocarcinoma; mesenchymal benign = -oma, malignant = sarcoma; hematopoietic = leukemia/lymphoma (always malignant).
Pearl
Three-layer classification: (1) benign vs malignant, (2) histogenetic origin, (3) molecular subtype (12 classes — reassigns ~1/10 patients).
NEW3-Step Formula
§1 Define · Histogenetic classification (the dominant Altucci-emphasized scheme) categorizes neoplasms by the tissue of origin and biological behavior, providing the basis for clinical nomenclature, prognosis, and therapy.
§2 Mechanism · EPITHELIAL tumors are the most common — benign: ADENOMA (glandular, e.g., colonic tubular adenoma), PAPILLOMA (surface finger-like, e.g., squamous papilloma); malignant: CARCINOMA in general, ADENOCARCINOMA (glandular epithelium — colon, lung, breast, prostate, pancreas), SQUAMOUS CELL CARCINOMA (stratified squamous — skin, esophagus, cervix, lung), TRANSITIONAL CELL CARCINOMA (urothelium), BASAL-CELL CARCINOMA (skin). MESENCHYMAL tumors — benign: lipoma (fat), fibroma, leiomyoma (smooth muscle — uterine fibroid), osteoma, chondroma, hemangioma; malignant SARCOMAS named for differentiation: liposarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, osteosarcoma, chondrosarcoma, angiosarcoma. HEMATOPOIETIC tumors are ALWAYS malignant: leukemias (AML, ALL, CML, CLL) and lymphomas (Hodgkin, non-Hodgkin). MIXED tumors: pleomorphic adenoma of salivary gland (epithelial + myoepithelial); teratomas arise from totipotent germ cells with all 3 germ layers. EPONYMS that look benign but are MALIGNANT: melanoma, lymphoma, glioblastoma, mesothelioma, seminoma. After this histogenetic step, malignant tumors undergo MOLECULAR reclassification (12 classes, independent of tissue) and STAGING/GRADING: grade G1–G4 (degree of differentiation), TNM stage (Tumor size + Nodes + Metastases). Tumor Mutation Burden and gene-fusion analysis (RNAseq across 33 tumor types) are emerging biomarkers.
§3 Clinical + Test · Practical exam approach: for any unknown tumor, state (i) benign vs malignant, (ii) tissue origin via the histogenetic name, (iii) molecular features if known (e.g., HER2 amp, IDH mut, BCR-ABL). Diagnostic confirmation = biopsy + IHC ± molecular panel.
Hyperplasia
Cellular Adaptations
Increase in cell number. Physiologic (endometrium) or pathologic (endometrial hyperplasia).
Pearl
Reversible. May predispose to malignancy if persistent.
NEW3-Step Formula
§1 Define · Hyperplasia is an increase in the number of cells in an organ or tissue, resulting from increased proliferation of differentiated cells or progenitor cells.
§2 Mechanism · The mechanism is driven by growth factor-induced signaling (e.g., TGF-alpha, HGF) or increased hormonal stimulation, which triggers the entry of quiescent cells into the cell cycle (G0 to G1 transition). It can be physiological, such as compensatory regeneration or hormonal changes, or pathological, which often serves as a fertile soil for subsequent cancerous mutations.
§3 Clinical + Test · A clinical example is Benign Prostatic Hyperplasia (BPH) or endometrial hyperplasia. Diagnosis is typically confirmed via ultrasound or biopsy; treatment may include alpha-blockers for BPH or hormonal regulation for endometrial cases.
Hypertrophy
Cellular Adaptations
Increase in cell size. Common in non-dividing cells (cardiac, skeletal muscle).
Pearl
Cardiac hypertrophy in HTN, aortic stenosis. Sarcomere addition.
NEW3-Step Formula
§1 Define · Hypertrophy is an increase in the size of cells resulting in an increase in the size of the organ, occurring in cells with limited capacity for division.
§2 Mechanism · The mechanism involves the activation of sensors (mechanical or trophic) that trigger signal transduction pathways like PI3K/AKT or G-protein coupled receptors. These pathways induce the expression of transcription factors (GATA4, NFAT) that increase the synthesis of structural proteins and organelles. In the heart, this often involves a switch to fetal isoforms of proteins like alpha-myosin heavy chain to beta-myosin heavy chain.
§3 Clinical + Test · A clinical example is Left Ventricular Hypertrophy (LVH) due to systemic hypertension. Diagnosis is made via echocardiography or EKG (Sokolow-Lyon criteria); management involves controlling blood pressure with ACE inhibitors or ARBs.
I
Imprinting
Epigenetics
Parent-of-origin-specific gene expression via differential methylation.
Pearl
Prader-Willi (paternal del 15q), Angelman (maternal del 15q).
NEW3-Step Formula
§1 Define · Genomic imprinting is an epigenetic phenomenon where certain genes are expressed in a parent-of-origin specific manner, with one allele being silenced via DNA methylation. It is characterized by non-equivalence of paternal and maternal genetic contributions at specific loci.
§2 Mechanism · During gametogenesis, imprinting marks (methyl groups) are erased and re-established based on the sex of the parent. In the offspring, the silenced (imprinted) allele is transcriptionally inactive, while the non-imprinted allele produces the necessary protein. If the single active allele is lost due to deletion or uniparental disomy, no functional protein is produced, leading to disease. Key mediators include DNA methyltransferases and long non-coding RNAs that regulate the chromatin state.
§3 Clinical + Test · Classic examples are Prader-Willi Syndrome (loss of paternal 15q11-q13) and Angelman Syndrome (loss of maternal UBE3A). Diagnosis is confirmed via methylation-specific PCR, MLPA, or FISH to detect copy number variations or imprinting defects.
K
Klinefelter Syndrome
Genetics
47,XXY. Tall stature, gynecomastia, small testes, infertility, learning issues.
Pearl
Most common cause of male hypogonadism. Increased FSH/LH, low testosterone.
NEW3-Step Formula
§1 Define · Klinefelter Syndrome is a chromosomal aneuploidy characterized by at least one extra X chromosome in a male, most commonly with a 47,XXY karyotype. It is typically caused by meiotic non-disjunction during parental gametogenesis.
§2 Mechanism · The extra X chromosome undergoes X-inactivation into a Barr body, but genes in the pseudoautosomal regions (PAR1/PAR2) escape inactivation and are overexpressed. This gene dosage imbalance leads to testicular dysgenesis and the destruction of seminiferous tubules. Consequently, Leydig cell dysfunction causes decreased testosterone, while loss of feedback inhibition results in elevated FSH and LH levels.
§3 Clinical + Test · Clinical features include tall stature, gynecomastia, and azoospermia. Diagnosis is established via G-banded karyotype analysis; management often involves lifelong testosterone replacement therapy.
Knudson Two-Hit
Tumor Suppressors
Tumor suppressors require biallelic inactivation. Familial cancers inherit one hit.
Pearl
Original example: retinoblastoma (RB gene).
NEW3-Step Formula
§1 Define · The Knudson Two-Hit hypothesis describes the mechanism for tumor suppressor gene inactivation, requiring both alleles to be lost or mutated to drive oncogenesis. This model explains why tumor suppressors behave recessively at a cellular level.
§2 Mechanism · In familial cases, the 'first hit' is a germline mutation present in every cell; a 'second hit' occurs somatically in a specific tissue, leading to loss of heterozygosity (LOH). In sporadic cases, both hits must occur somatically in the same cell lineage, which is statistically less frequent. Loss of both functional alleles eliminates the 'brake' on the cell cycle, such as pRb governing the G1-S transition. This leads to clonal expansion and genomic instability.
§3 Clinical + Test · The classic example is Retinoblastoma (RB1 gene); familial cases present bilaterally and earlier than sporadic cases. Diagnosis involves NGS for germline mutations and ophthalmologic examination; treatment may include chemotherapy or enucleation.
L
LDL in Atheroma
Cardiovascular
NEW · Low-Density Lipoprotein is the key atherogenic carrier — infiltrates intima, undergoes oxidation, drives foam-cell formation and inflammation.
Pearl
Every 1 mmol/L LDL ↓ = ~22% CV event reduction. PCSK9 inhibitors (alirocumab) ↓ LDL by ~60%.
NEW3-Step Formula
§1 Define · LDL (low-density lipoprotein) is the principal cholesterol-carrying lipoprotein in plasma and the central pathogenic driver of atherogenesis.
§2 Mechanism · When plasma LDL is elevated, particles penetrate dysfunctional endothelium and bind to intimal proteoglycans, where reactive oxygen species and myeloperoxidase generate OXIDIZED-LDL. Ox-LDL is cytotoxic to endothelium, chemotactic for monocytes, and engages scavenger receptors (CD36, SR-A, LOX-1) on macrophages — bypassing the normal LDL-receptor feedback — leading to unrestricted cholesterol uptake and FOAM-CELL transformation. Ox-LDL also activates NF-κB → IL-1β, TNF, MCP-1 amplifying inflammation. Genetic loss of LDL receptor (familial hypercholesterolemia) causes premature atherosclerosis.
§3 Clinical + Test · Measure LDL-C, ApoB, Lp(a). Treatment: high-intensity statin (HMG-CoA reductase inhibition ↑ hepatic LDL-R), ezetimibe (NPC1L1 inhibitor), PCSK9 inhibitors, bempedoic acid; LDL goal < 70 mg/dL (or < 55) in established ASCVD.
Leukemia
Anemia
Malignant clonal proliferation of hematopoietic cells in bone marrow.
Pearl
AML (Auer rods), ALL (children), CML (Philadelphia t(9;22) BCR-ABL), CLL (smudge cells).
NEW3-Step Formula
§1 Define · Leukemia is a group of malignant neoplasms originating from hematopoietic stem cells in the bone marrow, involving the uncontrolled proliferation of abnormal white blood cells. It is classified into acute (blast-rich) or chronic (mature-looking cells) and by lineage (myeloid vs. lymphoid).
§2 Mechanism · The pathogenesis typically involves chromosomal translocations that create fusion oncogenes or gain-of-function mutations in signaling proteins. For example, in CML, the t(9;22) translocation creates the BCR-ABL1 fusion protein, a constitutively active tyrosine kinase. This kinase activates downstream MAPK and PI3K/AKT pathways, shifting the marrow toward excessive granulocyte production and suppressing normal hematopoiesis. This results in marrow overcrowding, anemia, and thrombocytopenia.
§3 Clinical + Test · Chronic Myeloid Leukemia (CML) is defined by the Philadelphia chromosome, detected via FISH or RT-PCR. It is treated with Imatinib, a targeted tyrosine kinase inhibitor that blocks the BCR-ABL1 ATP-binding site.
Liquefactive Necrosis
Cell Death
Tissue digested by enzymes → fluid/pus. Classic in brain infarcts and bacterial abscesses.
Pearl
Why brain? Lack of structural protein and abundant lysosomes.
NEW3-Step Formula
§1 Define · Liquefactive necrosis is a pattern of cell death characterized by the complete digestion of dead cells, resulting in the transformation of the tissue into a liquid, viscous mass. It is the dominant form of necrosis in focal bacterial infections and CNS hypoxic injury.
§2 Mechanism · Hydrolytic enzymes (proteases, nucleases, lipases) released from lysosomes or recruited neutrophils rapidly degrade the cellular architecture. Unlike coagulative necrosis, the protein denaturation is secondary to the enzymatic digestion, leaving no 'ghost cells' or preserved framework. In the brain, the high lipid content and lack of a supporting connective tissue stroma favor this rapid liquefaction. The resulting debris is often creamy yellow (pus) due to dead leukocytes.
§3 Clinical + Test · Clinical examples include brain infarcts and pyogenic bacterial abscesses. Diagnosis is clinical and radiologic (e.g., CT/MRI showing fluid-filled cavities), confirmed by histology showing a liquid center without preserved tissue architecture.
Liver Cirrhosis
Cellular Adaptations
NEW · End-stage diffuse hepatic fibrosis with regenerative nodules surrounded by fibrous septa — distorts vasculature → portal hypertension and hepatic failure.
Pearl
Top causes: alcohol, HCV/HBV, NAFLD/NASH, hemochromatosis, autoimmune, Wilson, α1-antitrypsin. Classic transudative ascites (SAAG ≥ 1.1).
NEW3-Step Formula
§1 Define · Cirrhosis is the irreversible terminal stage of chronic liver disease defined histologically by bridging fibrosis and regenerative parenchymal nodules that destroy the normal hepatic architecture.
§2 Mechanism · Persistent injury (HCV, alcohol metabolites, free fatty acids in NASH) → hepatocyte apoptosis/necrosis → activation of KUPFFER cells and quiescent vitamin-A-storing HEPATIC STELLATE CELLS into myofibroblasts via TGF-β, PDGF, ROS, and endothelin-1. Myofibroblasts deposit type I collagen in the space of Disse → loss of fenestrations ('capillarization' of sinusoids) → ↑ intrahepatic resistance → PORTAL HYPERTENSION → varices, splenomegaly, ascites (transudate from ↑ hydrostatic + ↓ oncotic pressure due to hypoalbuminemia). Hepatocyte mass loss → coagulopathy, hyperestrogenism (spider angiomas, palmar erythema, gynecomastia), hyperammonemia → hepatic encephalopathy. Regenerative nodules + persistent injury → ↑ HCC risk.
§3 Clinical + Test · Diagnose with LFTs, INR, albumin, platelet count, US/elastography (FibroScan), MELD/Child-Pugh scoring, EGD for varices. Treat the cause (DAAs for HCV, abstinence, weight loss), nonselective β-blockers (propranolol) and band ligation for varices, spironolactone + furosemide for ascites, lactulose/rifaximin for encephalopathy, transplant for decompensation.
M
Marfan Syndrome
Genetics
AD mutation in FBN1 → defective fibrillin-1 → weak elastic tissue.
Pearl
Tall, arachnodactyly, lens dislocation (upward), aortic root dilation/dissection.
NEW3-Step Formula
§1 Define · Marfan Syndrome is an autosomal dominant connective tissue disorder caused by mutations in the FBN1 gene on chromosome 15q21, leading to a loss-of-function or dominant-negative defect in fibrillin-1.
§2 Mechanism · Fibrillin-1 is a structural glycoprotein that forms microfibrils in the extracellular matrix and normally sequesters TGF-beta; defective fibrillin-1 leads to excessive bioavailability of free TGF-beta. This signaling excess triggers overactive metalloproteinases and connective tissue degradation, particularly affecting the elastic fibers of the aorta, skeletal system, and ocular ligaments.
§3 Clinical + Test · A classic clinical manifestation is ectopia lentis (upward lens dislocation) and aortic root aneurysm. Diagnosis is confirmed by clinical criteria (Ghent nosology) and NGS for FBN1 mutations; treatment involves beta-blockers or ARBs (Losartan) to reduce TGF-beta signaling and aortic wall stress.
Metaplasia
Cellular Adaptations
Replacement of one mature cell type with another. Reversible if stimulus removed.
Pearl
Barrett's esophagus: squamous → columnar (GERD). Predisposes to adenocarcinoma.
NEW3-Step Formula
§1 Define · Metaplasia is a reversible adaptive process where one differentiated cell type (epithelial or mesenchymal) is replaced by another cell type better suited to withstand a specific chronic irritation or stress.
§2 Mechanism · It involves the 'reprogramming' of local tissue stem cells or undifferentiated mesenchymal cells through the action of cytokines, growth factors, and extracellular matrix components that alter gene expression. For instance, chronic acid reflux induces the transition of squamous esophageal cells to columnar intestinal cells to provide better acid resistance.
§3 Clinical + Test · Barrett’s Esophagus is the most common clinical example, where squamous epithelium becomes intestinal-like columnar epithelium. Diagnosis is made via endoscopy and histological biopsy; though reversible, persistent metaplasia can progress to dysplasia and adenocarcinoma.
Metastasis
Metastasis
Spread of malignant cells from primary to distant site.
Pearl
Cascade: invasion → intravasation → arrest → extravasation → colonization (rate-limiting).
NEW3-Step Formula
§1 Define · Metastasis is the process by which malignant tumor cells spread from a primary site to non-adjacent organs through a complex, multi-step cascade involving intravasation and extravasation.
§2 Mechanism · The cascade begins with Epithelial-Mesenchymal Transition (EMT), where E-cadherin is downregulated and SNAIL/TWIST upregulate N-cadherin; cells then secrete MMPs to degrade the basement membrane. After entering the circulation (intravasation) and surviving immune attack, the cells adhere to distant endothelium, exit the vessel (extravasation), and undergo Mesenchymal-Epithelial Transition (MET) to form secondary colonies.
§3 Clinical + Test · A common clinical example is breast cancer metastasizing to the bone or brain. Metastasis is assessed using TNM staging (M category) and imaging (PET/CT), and its presence typically necessitates systemic therapy rather than localized surgery alone.
MYC
Neoplasia
Transcription factor proto-oncogene. Translocation t(8;14) in Burkitt lymphoma.
Pearl
Starry sky pattern on biopsy; tumor lysis syndrome on treatment.
NEW3-Step Formula
§1 Define · MYC is a proto-oncogene encoding a transcription factor that acts as a master regulator of cell growth, metabolism, and protein synthesis; it is a gain-of-function oncogene frequently activated by translocation or amplification.
§2 Mechanism · Upon activation, the MYC protein heterodimerizes with MAX to bind E-box sequences, driving the expression of genes required for aerobic glycolysis (Warburg effect) and cell cycle progression (Cyclin D, CDKs). Overexpression bypasses cell cycle checkpoints, promoting autonomous proliferation and preventing terminal differentiation.
§3 Clinical + Test · The t(8;14) translocation of MYC to the IgH locus is the hallmark of Burkitt Lymphoma. Diagnosis is performed via FISH for the MYC rearrangement or IHC to detect protein overexpression, and treatment often involves aggressive multi-agent chemotherapy.
N
Necrosis
Cell Death
Accidental, ATP-deplete cell death with membrane rupture and inflammation.
Pearl
Patterns: coagulative, liquefactive, caseous, fat, fibrinoid, gangrenous.
NEW3-Step Formula
§1 Define · Necrosis is an unprogrammed, passive form of cell death resulting from severe injury, characterized by loss of membrane integrity, enzymatic digestion, and a significant inflammatory response.
§2 Mechanism · The mechanism begins with a 'point of no return' involving massive calcium influx, ATP depletion, and Mitochondrial Permeability Transition (MPT); this leads to lysosomal enzyme leakage and cellular swelling (oncosis). Digestion of the cell and leakage of intracellular contents into the interstitium trigger the recruitment of neutrophils and the release of pro-inflammatory cytokines.
§3 Clinical + Test · Clinical examples include Coagulative necrosis in myocardial infarction and Liquefactive necrosis in brain infarcts. Diagnosis is supported by clinical imaging and the detection of leaked intracellular biomarkers in the blood, such as Troponin-I in the case of cardiac necrosis.
Nervous System Tumors
Neoplasia
NEW · Primary CNS tumors classified by WHO 2021 by histology + molecular markers (IDH, 1p/19q, MGMT, H3K27, BRAF). Glioblastoma is most common malignant primary brain tumor in adults.
Pearl
Adults supratentorial = glioblastoma, meningioma, metastases. Children infratentorial = pilocytic astrocytoma, medulloblastoma, ependymoma, brainstem glioma.
NEW3-Step Formula
§1 Define · Nervous system tumors are a heterogeneous group of neoplasms arising from neuroepithelial, meningeal, lymphoid, or metastatic origin within the CNS or PNS, classified by the WHO 2021 system combining histology with molecular markers.
§2 Mechanism · ADULT primary tumors are predominantly SUPRATENTORIAL: Glioblastoma (GBM, WHO grade 4 astrocytoma — IDH-wildtype) shows pseudopalisading necrosis and microvascular proliferation; methylated MGMT predicts temozolomide response. Diffuse astrocytomas and oligodendrogliomas (1p/19q codeletion, IDH-mutant — better prognosis). Meningioma (extra-axial, dural tail, psammoma bodies, NF2 loss) — usually benign. Schwannoma (vestibular nerve, S100+, NF2). Primary CNS lymphoma (immunocompromised, EBV+). CHILDREN primary tumors are predominantly INFRATENTORIAL: Pilocytic astrocytoma (cystic + mural nodule, Rosenthal fibers, BRAF-KIAA1549 fusion — most benign), Medulloblastoma (PNET, small round blue cells, Homer-Wright rosettes, MYC/SHH/WNT subgroups), Ependymoma (4th ventricle, perivascular pseudorosettes), Brainstem glioma (DIPG, H3K27M mutation — poor prognosis). METASTASES (most common CNS tumor overall in adults) come from lung > breast > melanoma > renal > GI; classically multiple, at grey-white junction, well-circumscribed. Clinical: focal deficits, seizures, ↑ ICP (headache worse in morning, vomiting, papilledema), endocrine signs (pituitary).
§3 Clinical + Test · Diagnose with MRI + contrast (ring-enhancement in GBM/abscess/met), stereotactic biopsy with molecular profiling (IDH, MGMT, 1p/19q, H3K27). Treat with maximal safe resection + radiation + chemo (temozolomide in GBM); bevacizumab for recurrence; targeted therapy (BRAF/MEK inhibitors in BRAF-mutant).
Neutrophil
Inflammation
First responder of acute inflammation. Phagocytic; releases NETs.
Pearl
Hallmark cell of bacterial infection and acute inflammation.
NEW3-Step Formula
§1 Define · The neutrophil is the primary effector cell of acute inflammation, representing a type of polymorphonuclear leukocyte derived from myeloid precursors.
§2 Mechanism · Recruitment follows a vascular phase and occurs via a multi-step cascade: margination, rolling (selectins), adhesion (integrins/ICAM-1), and transmigration. Once in the tissue, they follow chemoattractants like IL-8 and C5a to the site of injury. Elimination of pathogens is achieved through phagocytosis, the release of reactive oxygen species (respiratory burst), and the formation of Neutrophil Extracellular Traps (NETs).
§3 Clinical + Test · In the tumor microenvironment, Prof. Castoria emphasizes N2-polarized neutrophils which promote progression via MMP-9 and VEGF. Their presence in an abscess is diagnostic of acute liquefactive necrosis.
O
Oncogene
Neoplasia
Mutated proto-oncogene with gain-of-function driving proliferation.
Pearl
RAS (point mutation), MYC (amplification/translocation), HER2 (amplification), BCR-ABL (translocation).
NEW3-Step Formula
§1 Define · An oncogene is a mutated or overexpressed version of a proto-oncogene that functions through a dominant gain-of-function mechanism, where a single mutant allele drives uncontrolled cell proliferation.
§2 Mechanism · Activation occurs via point mutations, gene amplification, or chromosomal translocations that render the protein constitutively active or resistant to degradation. These genes typically encode growth factors, receptor tyrosine kinases (RTKs), signal transducers, or transcription factors. The resulting signaling bypasses normal regulatory checkpoints, leading to autonomous cell growth and survival.
§3 Clinical + Test · A classic example is the BCR-ABL fusion gene in Chronic Myeloid Leukemia (CML). It is diagnosed via FISH or RT-PCR for the t(9;22) Philadelphia chromosome and targeted specifically by the tyrosine kinase inhibitor imatinib.
Oncosuppressor Genes
Tumor Suppressors
NEW · Italian/European synonym for tumor suppressor genes — recessive loss-of-function brakes on the cell cycle (RB, p53, p16, APC, BRCA1/2, PTEN, NF1, VHL).
Pearl
Always require BIALLELIC inactivation (Knudson). Distinguish gatekeepers (RB, p53, p16) from caretakers (BRCA1/2, MMR, NER).
NEW3-Step Formula
§1 Define · Oncosuppressor (tumor suppressor) genes encode proteins that restrain proliferation, repair DNA, or trigger apoptosis; their loss is recessive at the cellular level — both alleles must be inactivated for malignant transformation.
§2 Mechanism · Two functional classes: GATEKEEPERS (RB sequesters E2F at G1/S; p53 induces p21/GADD45/BAX after DNA damage; p16 inhibits CDK4/6) directly regulate the cycle; CARETAKERS (BRCA1/2 in HR, MMR genes in microsatellite repair, NER in xeroderma pigmentosum) preserve genome integrity. Inactivation occurs by point mutation, deletion, LOH, or epigenetic silencing (promoter hypermethylation). Some viruses functionally inactivate them: HPV E6 degrades p53, E7 binds RB.
§3 Clinical + Test · Li-Fraumeni (germline TP53), hereditary retinoblastoma (RB1), HBOC (BRCA1/2), FAP (APC). Diagnosis: NGS panel + LOH/MLPA; PARP inhibitors (olaparib) exploit synthetic lethality in BRCA carriers.
P
p53 (TP53)
Tumor Suppressors
'Guardian of the genome'. Senses DNA damage → arrest (p21), repair, or apoptosis (BAX↑).
Pearl
Mutated in >50% of all human cancers. Germline mutation = Li-Fraumeni.
NEW3-Step Formula
§1 Define · Known as the 'Guardian of the Genome,' TP53 is a tumor suppressor gene that functions through a recessive loss-of-function mechanism to maintain genomic stability.
§2 Mechanism · In response to DNA damage detected by ATM/ATR kinases, p53 is phosphorylated and stabilized, escaping degradation by its inhibitor MDM2. Active p53 acts as a transcription factor for p21 (CDKN1A), which induces G1 cell cycle arrest, GADD45 for DNA repair, and BAX for apoptosis if the damage is irreparable. Loss of p53 allows cells with damaged DNA to proliferate, leading to malignant transformation.
§3 Clinical + Test · Germline mutations cause Li-Fraumeni Syndrome, characterized by multiple early-onset cancers. Diagnosis is typically confirmed via NGS for point mutations or IHC showing protein accumulation in tumor cells.
PTEN
Tumor Suppressors
Lipid phosphatase that opposes PI3K. Loss → constitutive AKT signaling.
Pearl
Loss → immunotherapy resistance (T-cell exclusion, ↑PD-L1).
NEW3-Step Formula
§1 Define · PTEN (Phosphatase and Tensin Homologue) is a critical tumor suppressor gene that acts as a negative regulator of the PI3K/AKT/mTOR survival pathway.
§2 Mechanism · PTEN functions as a phosphatase that dephosphorylates PIP3 back into PIP2, effectively antagonizing PI3K activity. By reducing PIP3 levels, it prevents the recruitment and activation of AKT, thereby inhibiting downstream signals for cell growth, protein synthesis, and anti-apoptosis. Loss of PTEN leads to constitutive AKT activation and metabolic reprogramming favorable for tumor progression.
§3 Clinical + Test · PTEN loss is frequently seen in endometrial and prostate cancers. Cowden Syndrome is the associated germline condition characterized by multiple hamartomas, diagnosed via NGS of the PTEN gene.
Pus
Inflammation
NEW · Yellow-green purulent exudate composed of dead and dying neutrophils, liquefied necrotic tissue, edema fluid, and microorganisms.
Pearl
Hallmark of pyogenic bacterial infection (S. aureus, S. pyogenes, E. coli). Forms abscesses by liquefactive necrosis.
NEW3-Step Formula
§1 Define · Pus is a thick purulent exudate produced by acute suppurative inflammation, composed primarily of degenerated neutrophils ('pyocytes'), proteinaceous edema fluid, cellular debris, and viable or dead microorganisms.
§2 Mechanism · Pyogenic bacteria release chemoattractants (fMLP, LPS) and toxins; complement (C5a) and IL-8 mobilize massive neutrophil influx. Neutrophil azurophilic granules release myeloperoxidase, elastase, and ROS that kill bacteria but also digest surrounding tissue (liquefactive necrosis). The walled-off cavity of pus = ABSCESS; spread along tissue planes = phlegmon/cellulitis; pus within a preformed cavity (pleura, joint) = empyema.
§3 Clinical + Test · Diagnose by Gram stain + culture of aspirated pus; imaging (US/CT) localizes abscesses. Treatment: 'pus under pressure must be drained' — incision and drainage PLUS targeted antibiotics (anti-staph β-lactam, vancomycin if MRSA suspected).
R
RAS Pathway
Oncogenes
NEW · RAS (H-, K-, N-) is a small GTPase membrane switch. RAS-GTP → RAF → MEK → ERK (MAPK) → cell-cycle entry; also PI3K-AKT. Mutated in ≥ 30% of human cancers.
Pearl
Hot-spot codons 12, 13, 61. KRAS-G12C is most aggressive — targeted by sotorasib/adagrasib. Farnesyl transferase inhibitors (rare use) block membrane anchoring.
NEW3-Step Formula
§1 Define · RAS proteins (KRAS, HRAS, NRAS) are small membrane-anchored GTPases that act as molecular switches transducing signals from receptor tyrosine kinases to downstream proliferation, survival, and differentiation pathways.
§2 Mechanism · Inactive RAS-GDP is converted to active RAS-GTP by guanine-nucleotide exchange factors (GEFs such as SOS) after RTK activation (e.g., EGFR → GRB2-SOS). Active RAS-GTP binds and activates RAF (a serine/threonine kinase) → MEK1/2 (dual-specificity kinase) → ERK1/2 (MAPK) → phosphorylates ELK-1, MYC, cyclin D1, driving G1→S transition. RAS-GTP also activates PI3K → AKT → mTOR (survival), and RalGDS. INTRINSIC GTPase activity (accelerated by RAS-GAPs like NF1) returns RAS to the inactive GDP-bound state. Oncogenic point mutations at codons 12, 13, 61 lock RAS in the GTP state — resistant to GAP — producing constitutive MAPK/PI3K signaling. RAS requires FARNESYLATION for plasma-membrane anchoring (the inhibitable post-translational step).
§3 Clinical + Test · KRAS mutations: pancreatic (>90%), colorectal (~45%), NSCLC (~30%). Cetuximab/panitumumab (anti-EGFR) is INEFFECTIVE in KRAS-mutant CRC — always test before therapy. Sotorasib and adagrasib are KRAS-G12C-specific covalent inhibitors in NSCLC. BRAF V600E mutations downstream of RAS → vemurafenib/dabrafenib + trametinib.
RB1
Tumor Suppressors
Retinoblastoma protein. Binds E2F → blocks G1→S transition until phosphorylated.
Pearl
First tumor suppressor identified. Germline loss → bilateral retinoblastoma.
NEW3-Step Formula
§1 Define · RB1 is a prototypical tumor suppressor gene located on chromosome 13q14 that regulates the G1-S phase transition of the cell cycle via a recessive loss-of-function mechanism.
§2 Mechanism · In its active, hypophosphorylated state, the pRb protein binds and sequesters the E2F transcription factor, preventing the expression of S-phase genes. Upon stimulation by growth factors, Cyclin D-CDK4/6 complexes hyperphosphorylate pRb, causing it to release E2F and allow cell cycle progression. Loss of both alleles, as described by Knudson’s two-hit hypothesis, leads to permanent 'brake' release and uncontrolled division.
§3 Clinical + Test · Mutations result in Retinoblastoma (hereditary or sporadic) and increased risk for osteosarcoma. Clinical diagnosis utilizes fundoscopy, while genetic confirmation is achieved through Karyotype or NGS to identify the 'two hits'.
Reed-Sternberg Cell
Lymphoma
Large bi/multinucleated B-cell with 'owl-eye' nuclei. Diagnostic for Hodgkin lymphoma.
Pearl
CD15+ CD30+ CD45−. Origin: germinal center B-cell.
NEW3-Step Formula
§1 Define · Reed-Sternberg (RS) cells are large, multi-nucleated or bilobed B-cells with a characteristic 'owl-eye' appearance that are the hallmark of classic Hodgkin Lymphoma.
§2 Mechanism · These cells derive from germinal center B-cells but undergo 'crippled' somatic hypermutation, failing to express standard B-cell markers like CD20. They survive apoptosis by activating the NF-κB pathway via CD40 and TNFR signaling. RS cells secrete cytokines (IL-5, IL-13, TGF-β) and chemokines (CCL17, CCL22) to recruit a massive, non-neoplastic inflammatory infiltrate which constitutes 99% of the tumor mass.
§3 Clinical + Test · Clinical Example: Hodgkin Lymphoma, Nodular Sclerosis type. Diagnostic Test: Lymph node biopsy with Immunohistochemistry showing CD15+ and CD30+ positivity. Therapeutic Implication: Targeted therapy with Brentuximab vedotin (anti-CD30 antibody-drug conjugate).
S
Sickle Cell Disease
Genetics
AR HbS: Glu→Val at position 6 of β-globin. Sickling under deoxygenation, acidosis, dehydration.
Pearl
Vaso-occlusive crises, autosplenectomy, hand-foot syndrome in children.
NEW3-Step Formula
§1 Define · Sickle Cell Disease is an autosomal recessive hemoglobinopathy caused by a specific missense mutation (Glu6Val) in the HBB gene on chromosome 11.
§2 Mechanism · The mutation replaces glutamic acid with valine at position 6 of the β-globin chain, creating deoxygenated Hemoglobin S (HbS) which polymerizes into long fibers. These fibers distort erythrocytes into a sickle shape, leading to increased rigidity and membrane damage. This results in chronic extravascular hemolysis and microvascular occlusion, causing tissue ischemia and infarction.
§3 Clinical + Test · Clinical Example: Vaso-occlusive crisis or Acute Chest Syndrome. Diagnostic Test: Hemoglobin electrophoresis or HPLC (High-Performance Liquid Chromatography) showing HbS. Therapeutic Implication: Hydroxyurea to increase fetal hemoglobin (HbF) levels.
Src
Oncogenes
NEW · First proto-oncogene discovered (v-Src in Rous sarcoma virus). Non-receptor tyrosine kinase regulating adhesion, motility, invasion, and proliferation.
Pearl
Activated by loss of inhibitory C-terminal Tyr530 phosphorylation. Targeted by dasatinib and bosutinib in CML and Ph+ ALL.
NEW3-Step Formula
§1 Define · Src (c-SRC) is the prototypical non-receptor tyrosine kinase and the first proto-oncogene ever discovered (1976, Bishop & Varmus), encoded on chromosome 20q11.
§2 Mechanism · Domain structure: SH4 (myristoylation membrane anchor), unique, SH3 (binds PXXP), SH2 (binds pY), kinase domain, and a C-terminal regulatory tail. INACTIVE conformation = phosphorylated Tyr530 (by Csk) binds the intramolecular SH2 domain, folding the protein into an autoinhibited closed state. Dephosphorylation of Tyr530 or competitive SH2 displacement releases the kinase, allowing autophosphorylation of activation-loop Tyr419. Active Src phosphorylates substrates governing cell-matrix adhesion (FAK, paxillin at focal adhesions), cytoskeletal remodeling (cortactin), invasion (MMP induction), proliferation (STAT3, MAPK), and survival. Constitutive Src activation in colon, breast, and pancreatic cancers correlates with metastatic potential.
§3 Clinical + Test · v-Src lacks the C-terminal regulatory tail — permanently active and oncogenic. Therapeutic Src/Abl dual inhibitors: DASATINIB and BOSUTINIB (CML, Ph+ ALL, especially imatinib-resistant T315I clones).
T
Tamoxifen
Hormone Malignancies
Selective Estrogen Receptor Modulator. Antagonist in breast, agonist in endometrium/bone.
Pearl
DVT and endometrial cancer risk. Used in ER+ breast cancer.
NEW3-Step Formula
§1 Define · Tamoxifen is a Selective Estrogen Receptor Modulator (SERM) used in the treatment and prevention of hormone-receptor-positive breast cancers.
§2 Mechanism · It acts as a competitive antagonist by binding to Estrogen Receptor α (ERα) in breast tissue, preventing estrogen from inducing the expression of proliferation genes like Cyclin D1 and MYC. In contrast, it acts as an agonist in the bone (preventing osteoporosis) and endometrium. This tissue-specific action is mediated by the recruitment of different co-activators or co-repressors to the cell nucleus.
§3 Clinical + Test · Clinical Example: ER-positive/Luminal A breast cancer. Diagnostic Test: Immunohistochemistry (IHC) for ER/PR status on tumor biopsy. Therapeutic Implication: Standard adjuvant endocrine therapy for 5–10 years.
Thalassemia
Anemia
AR. Reduced synthesis of α or β globin chains → microcytic anemia.
Pearl
α-thal: gene deletions. β-thal major: skull 'crew-cut', extramedullary hematopoiesis.
NEW3-Step Formula
§1 Define · Thalassemias are a heterogeneous group of autosomal recessive disorders characterized by a reduced or absent synthesis of α- or β-globin chains (Loss of Function).
§2 Mechanism · Imbalanced globin chain synthesis leads to the accumulation of unpaired free chains, which are toxic and precipitate within erythroid precursors. In β-thalassemia, excess α-chains cause membrane damage and premature destruction of RBCs in the bone marrow (ineffective erythropoiesis) and spleen. This leads to severe anemia, extramedullary hematopoiesis, and reactive bone marrow expansion.
§3 Clinical + Test · Clinical Example: β-Thalassemia Major (Cooley's anemia). Diagnostic Test: CBC showing microcytic anemia and hemoglobin electrophoresis showing absence of HbA and increased HbF/HbA2. Therapeutic Implication: Chronic blood transfusions and iron chelation therapy.
Transudate
Hemodynamics
NEW · Low-protein (<3 g/dL), cell-poor fluid from hemodynamic imbalance — NOT inflammatory.
Pearl
Top causes: liver cirrhosis, CHF, nephrotic syndrome, hypoalbuminemia. Light's criteria all NEGATIVE.
NEW3-Step Formula
§1 Define · A transudate is an ultrafiltrate of plasma with low protein content (< 3 g/dL), low specific gravity (< 1.012), and few cells, arising from altered hydrostatic or oncotic pressures with INTACT vascular permeability.
§2 Mechanism · Most common driver = LIVER CIRRHOSIS: portal hypertension ↑ sinusoidal hydrostatic pressure + impaired albumin synthesis ↓ oncotic pressure → ascites. CHF raises systemic venous pressure → bilateral pleural effusions and peripheral pitting edema. Nephrotic syndrome (>3.5 g/day proteinuria) depletes albumin → generalized anasarca. Light's criteria are all NEGATIVE: pleural/serum protein < 0.5, pleural/serum LDH < 0.6, pleural LDH < 2/3 upper normal.
§3 Clinical + Test · Diagnose with diagnostic paracentesis/thoracentesis + SAAG (serum-ascites albumin gradient ≥ 1.1 g/dL = portal HTN). Treat the underlying disease — diuretics (spironolactone for cirrhosis), salt restriction, TIPS if refractory.
Trisomy 21
Genetics
Down syndrome. Most common chromosomal disorder. Maternal age risk factor.
Pearl
AV septal defects, duodenal atresia, ↑risk of AML/ALL, early Alzheimer.
NEW3-Step Formula
§1 Define · Trisomy 21 (Down Syndrome) is a chromosomal aneuploidy characterized by the presence of a third copy of chromosome 21, usually due to meiotic non-disjunction.
§2 Mechanism · The extra genetic material leads to the overexpression of genes including APP (amyloid precursor protein), SOD1, and DYRK1A. Maternal meiosis I non-disjunction accounts for 95% of cases, while 4% result from Robertsonian translocations (typically 14;21). This gene dosage imbalance disrupts normal embryonic development, particularly affecting the craniofacial structures, heart, and central nervous system.
§3 Clinical + Test · Clinical Example: Pediatric patient with hypotonia, epicanthal folds, and Atrioventricular Canal Defect. Diagnostic Test: Karyotype analysis (47,XY,+21). Therapeutic Implication: Early screening for congenital heart disease and Hirschsprung disease.
Tuberculosis
Inflammation
NEW · Chronic granulomatous infection by Mycobacterium tuberculosis with CASEATING granulomas, Langhans giant cells, and acid-fast bacilli.
Pearl
Ghon complex (peripheral lesion + hilar node) = primary TB. Reactivation → upper-lobe cavitary disease. Treatment: RIPE (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) × 2 months then RI × 4.
NEW3-Step Formula
§1 Define · Tuberculosis is a chronic granulomatous infectious disease caused by Mycobacterium tuberculosis, characterized by Type IV (delayed-type) hypersensitivity and the formation of caseating epithelioid granulomas.
§2 Mechanism · Inhaled droplet nuclei deposit in mid/lower-lung alveoli → ingested by alveolar macrophages but resist killing (mycobacterial cord factor, mycolic acid, sulfatides inhibit phagolysosome fusion) → intracellular proliferation. After 3 weeks, antigens presented on MHC-II prime CD4+ Th1 cells which release IFN-γ → activates macrophages to epithelioid cells and Langhans-type multinucleated giant cells (nuclei in horseshoe). Center develops caseous (cheese-like, lipid-rich) necrosis. PRIMARY TB: subpleural Ghon focus + hilar lymphadenopathy = Ghon complex (Ranke complex if calcified) — usually asymptomatic, contained as latent TB. REACTIVATION (post-primary) TB: typically apical/posterior upper-lobe cavities (high pO2 favors aerobic Mtb), fibrosis, hemoptysis. MILIARY TB: lymphohematogenous spread → millet-seed lesions throughout lungs, liver, spleen, kidneys, meninges, vertebrae (Pott disease). Immunosuppression (HIV, anti-TNF biologics) reactivates latent infection.
§3 Clinical + Test · Diagnose: PPD/Mantoux (≥ 5/10/15 mm cut-offs by risk), IGRA (QuantiFERON, T-SPOT — no BCG cross-reaction), sputum AFB smear (Ziehl-Neelsen) ×3 + culture (gold standard) + Xpert MTB/RIF PCR. CXR: upper-lobe cavities, miliary pattern. Treat: 2 months RIPE + 4 months RI (DOT); MDR/XDR → fluoroquinolones, linezolid, bedaquiline. Pyridoxine (B6) with isoniazid to prevent neuropathy.
Tumor Suppressor Gene
Tumor Suppressors
Gene whose loss-of-function promotes cancer. Requires biallelic inactivation.
Pearl
TP53, RB, APC, BRCA1/2, PTEN, NF1, VHL, WT1.
NEW3-Step Formula
§1 Define · Tumor suppressor genes are protective genes that normally inhibit cell proliferation, repair DNA, or induce apoptosis; they typically follow a recessive Loss-of-Function (LoF) pattern where both alleles must be inactivated to promote malignancy.
§2 Mechanism · Loss occurs via Knudson’s two-hit hypothesis, where a first hit (germline or somatic) and a second hit (somatic mutation or LOH) eliminate the 'brakes' on the cell cycle. Key proteins like pRb sequester E2F to block G1-S transition, while p53 responds to DNA damage by upregulating p21 to arrest the cycle or BAX to trigger apoptosis. Absence of these proteins lead to unregulated genomic instability and clonal expansion.
§3 Clinical + Test · Retinoblastoma is a classic example caused by biallelic loss of RB1, while Li-Fraumeni syndrome involves germline TP53 mutations. Diagnosis is confirmed by NGS for point mutations or CGH-array for locus deletions.
Turner Syndrome
Genetics
45,X. Short stature, primary amenorrhea, streak ovaries, webbed neck.
Pearl
Coarctation of aorta, horseshoe kidney, lymphedema in infancy.
NEW3-Step Formula
§1 Define · Turner Syndrome is a chromosomal disorder in females characterized by complete or partial monosomy of the X chromosome (45,X), occurring most frequently due to paternal meiotic non-disjunction.
§2 Mechanism · The loss of the second X chromosome leads to the haploinsufficiency of genes in the pseudoautosomal regions (PAR1/2) that normally escape X-inactivation, such as the SHOX gene. In the ovaries, this deficiency triggers accelerated oocyte atresia and replaces functional tissue with fibrous 'streak' gonads. Lack of estrogen result in primary amenorrhea and failure of secondary sexual characteristic development.
§3 Clinical + Test · Clinical features include short stature, webbed neck, and coarctation of the aorta. Diagnosis is definitively established via peripheral blood karyotype; treatment often involves growth hormone and estrogen replacement therapy.
Type 1 Diabetes
Diabetes
NEW · Autoimmune destruction of pancreatic β-cells → absolute insulin deficiency. Childhood onset, lean phenotype, prone to DKA.
Pearl
HLA-DR3/DR4 association; autoantibodies anti-GAD65, anti-IA2, anti-insulin, anti-ZnT8. Lifelong insulin therapy.
NEW3-Step Formula
§1 Define · Type 1 Diabetes Mellitus is an autoimmune disease in which T-cell-mediated destruction of pancreatic β-cells in the islets of Langerhans results in absolute insulin deficiency, typically presenting in childhood or adolescence.
§2 Mechanism · Genetic susceptibility (HLA-DR3, HLA-DR4, polymorphisms in CTLA4, PTPN22) combined with environmental triggers (enterovirus, coxsackie B, cow-milk proteins) → loss of immune tolerance → CD8+ cytotoxic T cells infiltrate islets (insulitis) and destroy β-cells via perforin/granzyme and Fas-FasL. CD4+ Th1 cells release IFN-γ; autoantibodies against GAD65, IA-2, insulin, and ZnT8 precede clinical disease by years. When > 80–90% of β-cells are destroyed, insulin secretion fails → unrestrained hepatic gluconeogenesis and lipolysis → hyperglycemia, polyuria/polydipsia, weight loss; in severe deficiency, ↑ glucagon and free fatty acid β-oxidation produce ketone bodies → diabetic ketoacidosis (DKA: pH < 7.3, HCO3 < 18, anion-gap, ketonuria, Kussmaul breathing, fruity breath).
§3 Clinical + Test · Diagnose with FPG ≥ 126, random ≥ 200 + symptoms, HbA1c ≥ 6.5%; confirm autoimmune etiology with autoantibody panel and low C-peptide. Treat with basal-bolus insulin (glargine + lispro) or insulin pump + CGM; manage DKA with IV fluids, insulin infusion, K⁺ repletion.
Type 2 Diabetes
Diabetes
NEW · Insulin resistance + relative β-cell insufficiency. Adult onset, obesity-linked, strong genetic predisposition. Most common form (~90%).
Pearl
Complications: microvascular (retinopathy, nephropathy, neuropathy) + macrovascular (CAD, stroke, PAD, gangrene). ROS-driven endothelial injury via AGEs/RAGE.
NEW3-Step Formula
§1 Define · Type 2 Diabetes Mellitus is a chronic metabolic disorder defined by peripheral insulin resistance plus relative β-cell secretory failure, accounting for ~90% of diabetes cases and strongly linked to obesity, sedentary lifestyle, and genetics.
§2 Mechanism · Adipose-tissue expansion → release of free fatty acids, TNF-α, IL-6, resistin and ↓ adiponectin → serine-phosphorylation of IRS-1 → impaired PI3K-AKT signaling → ↓ GLUT4 translocation in muscle/fat and ↑ hepatic gluconeogenesis. β-cells initially compensate by hypersecreting insulin (hyperinsulinemia) but eventually fail due to glucotoxicity, lipotoxicity, ER stress, and amyloid (IAPP/amylin) deposition in islets. Chronic hyperglycemia drives complications through FOUR mechanisms: (1) non-enzymatic glycation forming Advanced Glycation End-products (AGEs) that bind RAGE → NF-κB → ROS and inflammation; (2) polyol pathway — aldose reductase converts glucose to sorbitol → osmotic stress in lens (cataract), Schwann cells (neuropathy), retina; (3) hexosamine pathway → TGF-β; (4) PKC activation → VEGF (retinopathy), endothelin-1, NADPH oxidase. ROS generated in mitochondria injure retinal capillary endothelium → microaneurysms, dot/blot hemorrhages, cotton-wool spots, neovascularization → diabetic RETINOPATHY. Other complications: nephropathy (Kimmelstiel-Wilson nodules), peripheral neuropathy, CAD, stroke, PAD with diabetic GANGRENE (combined ischemia + neuropathy + immunosuppression — typically WET, liquefactive necrosis with superimposed polymicrobial infection).
§3 Clinical + Test · Diagnose with HbA1c ≥ 6.5%, FPG ≥ 126, 2-h OGTT ≥ 200. First-line therapy: metformin (↓ hepatic gluconeogenesis). Add GLP-1 agonists (semaglutide — weight loss, CV benefit) and SGLT2 inhibitors (empagliflozin — renal/CV protection). Annual screening: retinal exam, urine ACR, foot exam, lipids.
V
VEGF
Neoplasia
Vascular Endothelial Growth Factor. Master regulator of angiogenesis.
Pearl
Target of bevacizumab (anti-VEGF mAb). Side effects: HTN, bleeding, impaired wound healing.
NEW3-Step Formula
§1 Define · Vascular Endothelial Growth Factor (VEGF) is a critical pro-angiogenic signaling protein produced by cells to stimulate the formation of new blood vessels from existing vasculature.
§2 Mechanism · Stimulated by hypoxia-inducible factor (HIF-1α) in response to low oxygen, VEGF binds to receptor tyrosine kinases (VEGFR-1/2) on endothelial cells. This activates the MAPK and PI3K pathways, leading to endothelial cell proliferation, increased vascular permeability, and matrix metalloproteinase (MMP) secretion for basement membrane degradation. The resulting 'leaky' vessels support tumor growth and provide a route for intravasation in the metastatic cascade.
§3 Clinical + Test · VEGF is overexpressed in most solid tumors and is a hallmark of the 'angiogenic switch.' Therapeutic inhibition is achieved with Bevacizumab (anti-VEGF monoclonal antibody) or kinase inhibitors like Sunitinib.
X
X-Linked Recessive
Genetics
Males hemizygous, affected. Females heterozygous = carriers. No male-to-male transmission.
Pearl
DMD, hemophilia A/B, G6PD deficiency, Lesch-Nyhan.
NEW3-Step Formula
§1 Define · X-linked recessive inheritance occurs when a mutation in a gene on the X chromosome causes the phenotype to be expressed in all males (hemizygous) and only in females who are homozygous for the mutation.
§2 Mechanism · Females are typically asymptomatic carriers but can show variable symptoms due to skewed X-inactivation (lyonization), where the wild-type X is silenced in a majority of cells. Affected fathers pass the mutation to all daughters (obligate carriers) but no sons, while carrier mothers have a 50% chance of passing the trait to each offspring. The loss-of-function mutation usually involves structural proteins or critical enzymes.
§3 Clinical + Test · Duchenne Muscular Dystrophy (DMD) and Hemophilia A are classic examples. Diagnosis utilizes MLPA to detect exon deletions in DMD or NGS; gene therapy and exon-skipping drugs (eteplirsen) are emerging treatments.